This phase I/II trial is trying to understand how safe and tolerable a new immunotherapy is for the treatment of advanced cancer.
This trial is treating patients with advanced solid cancers, in particular patients with melanoma or renal cell carcinoma.
This is a systemic therapy trial.
You may be able to join this trial if:
- You have had treatment, but your cancer has come back.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Phase 1/2 Study of ALKS 4230 Administered Intravenously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors - ARTISTRY-1
Eligible patients will assigned to one of two groups. In these groups, patients will either receive the investigational immunotherapy (ALKS 4230) alone via intravenous infusion over a 30 minute period, daily, for five consecutive days; OR in combination with intravenous pembrolizumab on the first day of each cycle.
Recruiting Hospitals Read More